References
- Murteira S, Ghezaiel Z, Karray S, et al. Drug reformulations and repositioning in pharmaceutical industry and its impact on market access: reassessment of nomenclature. J Market Access Health Policy. 2013;1:1.
- PriceWaterhouseCoopers. Pharma 2020: the vision. New York: PriceWaterhouseCoopers; 2007.
- Hemphill CS, Sampat BN. Evergreening, patent challenges, and effective market life in pharmaceuticals. J Health Econ. 2012;31(2):327–7.
- Murteira S, Millier A, Ghezaiel Z, et al. Drug reformulations and repositioning in the pharmaceutical industry and their impact on market access: regulatory implications. J Market Access Health Policy. 2014;2:22813. DOI:10.3402/jmahp.v2.22813
- Allarakhia M. Open-source approaches for the repurposing of existing or failed candidate drugs: learning from and applying the lessons across diseases. Drug Des Devel Ther. 2013;7:753–766.
- Hardman JG, Limbird LE, Molinoff PB, et al. Goodman & Gilman’s the pharmacological basis of therapeutics: section III Chapter 12 neurotransmission and the central nervous system. 11th ed. New York: McGraw-Hill; 2008. p. 265–578.
- Aminoff MJ, Boller F, Swaab DF. Handbook of clinical neurology: neurobiology of psychiatric disorders: foreword. Volume 106. Amsterdam, The Netherlands: Elsevier B.V; 2012. p. 2–760.
- World Health Organization. Regional estimates for 2000-2011: disease Burden. WHO Health Statistics and information systems); 2014 [Online]. Available from: http://www.who.int/healthinfo/global_burden_disease/estimates_regional/en/index1.html
- Pangalos MN, Schechter LE, Hurko O. Drug development for CNS disorders: strategies for balancing risk and reducing attrition. Nat Rev Drug Discov. 2007 Jul;6:521–532. DOI:10.1038/nrd2094
- Pardridge WM. Why is the global CNS pharmaceutical market so under-penetrated? Drug Discov Today. 2002 Jan 1;7(1):5–7.
- Riordan HJ, Cutler HR. The death of CNS drug development: overstatement or Omen? J Clin Stud. 2011;3:12–15.
- Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov. 2004;3:711–715.
- Murteira S, Millier A, Toumi M. Drug repositioning and reformulation in pharmaceutical industry and its impact on market access: market access implications. J Market Access Health Policy. 2014;2:22814. DOI:10.3402/jmahp.v2.22814
- Van Nooten F, Holmstrom S, Green J, et al. Health economics and outcomes research within drug development: challenges and opportunities for reimbursement and market access within biopharma research. Drug Discov Today. 2012 Jun;17(11–12):615–622.
- Levy AR, Mitton C, Johnston KM, et al. International comparison of comparative effectiveness research in five jurisdictions: insights for the US. Pharmacoeconomics. 2010;28(10):813–830.
- Sleigh SH, Barton CL. Repurposing strategies for therapeutics. Pharm Med. 2010;24(3):151–159.
- Padhy BM, Gupta YK. Drug repositioning: re-investigating existing drugs for new therapeutic indications. J Postgrad Med. 2011 Apr-Jun;57(2):153–160.
- Sekhon BS. Repositioning drugs and biologics: retargeting old/existing drugs for potential new therapeutic applications. J Pharm Educ Res. 2013 6;4(1):1–15.
- Murteira S, Hammi EE, Toumi M. Fixing the price of the orphan drug Siklos®: the Council of State takes over the decision. Eur J Health Law. 2014;21(5):505–515 .
- Bejjani BP, Damier P, Arnulf I, et al. Transient acute depression induced by high-frequency deep-brain stimulation. N Engl J Med. 1999 May 13;340(19):1476–1480.
- Martinez-Ramirez D, Hu W, Bona AR, et al. Update on deep brain stimulation in Parkinson’s disease. Transl Neurodegener. 2015 Jun;27(4):12.
- Commission Expert Group on Safe and Timely Access to Medicines for Patients (“STAMP”). Repurposing of established medicines/active substances. Agenda item 3. 2016 Mar 10 [Internet]; [ cited 2016 Sep 26]. Available from: http://ec.europa.eu/health/files/committee/stamp/2016-03_stamp4/3_repurposing_of_established_medicines_background_paper.pdf
- AstraZeneca. Novel collaboration with Medical Research Council gives UK academia access to AstraZeneca compounds. 2015 Feb [Internet]; [ cited 2016 Sep 26]. Available from: https://www.astrazeneca.com/content/dam/az/Our-Science/Partnering/case-studies/Feb15-Medical_Research_Council_Collaboration_Case_Study_UK-External-Final.pdf
- Institut National du Cancer (INCa). Le programme AcSé [Internet]; [ cited 2016 Sep 26]. Available from: http://www.e-cancer.fr/Professionnels-de-la-recherche/Recherche-clinique/Le-programme-AcSe
- NIH website. National Center for Advancing Translational Sciences (NCATS). Mission [Internet]; [ cited 2016 Sep 26]. Available from: https://www.nih.gov/about-nih/what-we-do/nih-almanac/national-center-advancing-translational-sciences-ncats
- NIH website. News releases: NIH launches collaborative program with industry and researchers to spur therapeutic development. 2012 May 3 [Internet]; [ cited 2016 Sep 26]. Available from: https://www.nih.gov/news-events/news-releases/nih-launches-collaborative-program-industry-researchers-spur-therapeutic-development